Patents by Inventor David Alcorta

David Alcorta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11992697
    Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: May 28, 2024
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Publication number: 20220226666
    Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.
    Type: Application
    Filed: March 21, 2022
    Publication date: July 21, 2022
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Patent number: 11305131
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: April 19, 2022
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark DeWhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Patent number: 11207409
    Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: December 28, 2021
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Frederic A. Bourke, Jr., Mark Dewhirst, Neil Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada, Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder
  • Publication number: 20200009398
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Application
    Filed: August 29, 2019
    Publication date: January 9, 2020
    Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITY
    Inventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Frederic A. BOURKE, JR., Harold WALDER, Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
  • Patent number: 10441810
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: October 15, 2019
    Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder, Frederic A. Bourke, Jr., Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
  • Publication number: 20180344850
    Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Frederic A. BOURKE, JR., Mark DEWHIRST, Neil SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA, Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER
  • Publication number: 20170157418
    Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
    Type: Application
    Filed: February 16, 2017
    Publication date: June 8, 2017
    Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITY
    Inventors: Mark OLDHAM, Zakaryae FATHI, Wayne F. BEYER, Harold WALDER, Frederic A. BOURKE, JR., Mark DEWHIRST, Neil L. SPECTOR, Paul YOON, Justus ADAMSON, David ALCORTA, Kim LYERLY, Leihua LIU, Takuya OSADA
  • Publication number: 20120004130
    Abstract: Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease.
    Type: Application
    Filed: June 3, 2011
    Publication date: January 5, 2012
    Inventors: Dawn R. MATTOON, Barry Schweitzer, David Alcorta, Dhavalkumar Patel, Ronald Falk
  • Publication number: 20080254482
    Abstract: Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease.
    Type: Application
    Filed: November 21, 2007
    Publication date: October 16, 2008
    Applicant: Invitrogen Corporation
    Inventors: Dawn R. Mattoon, Barry Schweitzer, David Alcorta, Dhavalkumar Patel, Ronald Falk